Login

Journal Front Page

News & Events

  • Call for article for January 2027 issue
    • Submissions of Review, Research Article, Short Communication and Case study are being accepted for the current and future issues before 15 December, 2026 of this journal by online process or editor@ajper.com, or ajper.editor@gmail.com. Further information can be found at www.ajper.com.
  • October 2026 Issue published
    • Dear Researcher, It Pleased to inform you that, Asian Journal of Pharmaceutical Education and Research, has successfully launch Volume 15, Issue 4 (October 2026 Issue). You can find the article on http://ajper.com/current_issue.php Article also invited for the Next coming Issue from your side. For More details Visit: www.ajper.com
  • Application For Reviewer
    • We are now going to reconstitute our editorial board members of Reviewer. Please send your resume at ajper.editor@gmail.com and be a part of the editorial board member as Reviewer.
  • AJPER Impact facor
    • It is to pleasure that Ajper SJIF imact facor has increse from 5.019 to 7.014. Also global impact factor incresed from 0.654 to 0.765.
  • ICV
    • AJPER Rank with Index Copernicus Value 61.10 due to high reputation at International Level

Abstract

FORMULATION AND CHARACTERIZATION OF LIPOSOMAL HYDROGEL OF BARICITINIB FOR MANAGEMENT OF DERMATITIS

Harsh Dubey*, Satkar Prasad

RKDF School of Pharmaceutical Sciences, Bhabha University, Bhopal (M.P.)

ABSTRACT

Baricitinib is a selective Janus kinase (JAK) inhibitor widely used in the management of inflammatory skin disorders; however, its therapeutic efficacy through conventional dosage forms is limited by poor skin retention and the need for frequent application. The present study aimed to develop and optimize a Baricitinib-loaded liposomal gel for sustained topical drug delivery. Liposomes were prepared using the ethanol injection method by varying the concentrations of Soya phosphatidylcholine (4–9% w/v) and Span 80 (2–7% w/v), while maintaining the drug concentration (2% w/w) and ethanol volume (5 mL) constant. Six formulations (F1–F6) were evaluated for vesicle size and entrapment efficiency. Among them, formulation F5 exhibited the smallest vesicle size (185.50 ± 7.45 nm), highest entrapment efficiency (73.45 ± 0.78%), and a zeta potential of −36.52 mV, indicating good colloidal stability. The optimized liposomal dispersion was incorporated into a Carbopol gel and evaluated for physicochemical characteristics, including drug content, pH, spreadability, viscosity, and in vitro drug release. The optimized liposomal gel (LG3) demonstrated satisfactory drug content (99.24 ± 0.21%), skin-compatible pH (6.98 ± 0.07), appropriate viscosity (4628 ± 25 cps), and acceptable spreadability (10.18 ± 0.65 g•cm/sec). The formulation exhibited sustained drug release, achieving 99.24% cumulative release over 10 hours. Drug release kinetic analysis revealed that the release profile best fitted the Higuchi model (R² = 0.9980), indicating diffusion-controlled release. These findings suggest that the developed Baricitinib liposomal gel is a promising sustained-release topical drug delivery system with improved formulation characteristics and potential for enhanced therapeutic efficacy.

Keywords: Baricitinib, Liposomes, Liposomal Gel, Sustained Drug Release, Ethanol Injection Method, Soya Phosphatidylcholine, Span 80, Entrapment Efficiency, Topical Drug Delivery, Higuchi Model.


[Full Text Article]